Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kiniksa Pharmaceuticals International, plc

NASDAQ: KNSA · Life Sciences · 10 alerts · CIK 1730430

Share price
$94.23Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kiniksa Pharmaceuticals International, plc filings on SEC EDGAR ↗

4:36 PM ET 10-Q
Financial Results

Kiniksa Pharmaceuticals International Q3 2026 Results: Net Income $47.3M, Up 156.8% YoY

Kiniksa Pharmaceuticals reported total product revenue of $285.97 million for the third quarter of 2026, a significant increase from $180.86 million in the prior year. Net income for the quarter rose to $47.35 million, while the company maintained a strong liquidity position with $568.76 million in cash, cash equivalents, and short-term investments.

Key figure
Net income $47.3M · +156.8% YoY
7:33 AM ET 8-K
Financial Results

Kiniksa Pharmaceuticals International Financial Results

Kiniksa Pharmaceuticals reported Q3 2026 financial results, highlighted by ARCALYST net product revenue of $286.0 million, a 58% year-over-year increase. The company raised its full-year 2026 ARCALYST net product revenue guidance to a range of $1.045 billion to $1.050 billion.

“Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third quarter, strong commercial execution led to gains in patient and physician adoption, resulting in revenue of $286.0 million and positioning ARCALYST to achieve blockbuster status this year”

Sanj K. Patel, Chairman & Chief Executive Officer of Kiniksa

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.